A Comprehensive Review: Novel Drug Approaches in The Breast Cancer Treatment

Breast Cancer (BC) is a carcinoma of breast tissues, the major recurrent cancer in women and also the foremost cause of death with approximate 5 million annual deaths worldwide. Globally, women are diagnosed with breast cancer (BC) more often than any other malignancy. Four molecular subtypes of this heterogeneous disease luminal A, luminal B, HER2, and triple-negative breast cancer (TNBC) can be distinguished based on the expression of the progesterone and oestrogen receptors, as well as the overexpression of the human epidermal growth factor receptor 2 (HER2). Endocrine and anti- HER2 medicines, which target these receptors, are the current personalised therapy for BC. These treatments, together with radiation and chemotherapy, can have serious side effects and cause patients to become resistant to the drugs. Furthermore, there are no established therapies for TNBC. Therefore, it is essential to have a deeper understanding of how new medications are developed that are more targeted and efficient in treating each BC subgroup.